Company
Headquarters: New York, NY, United States
Employees: 1
CEO: Mr. William E. Luther
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Lescarden Inc. researches, tests, develops, and sells medications for the control and cure of various diseases in the United States, Europe, and South Korea. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers. The company also offers a line of Catrix-based wound and skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, it provides nutritional supplements, such as Bio-Cartilage and Poly-NAG, a patented glucosamine polymer; and licenses its technologies for commercialization by other companies. Lescarden Inc. was founded in 1960 and is based in New York, New York.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Lescarden, Inc. has the following listings and related stock indices.
Stock: OTC: LCAR wb_incandescent